It is very uncertain whether probiotics changes minor adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes minor adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
Probiotics showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
It is very uncertain whether antibiotics plus probiotics changes withdrawals due to adverse events compared with placebo or no intervention (very low certainty).